Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Size Price Stock Quantity  
In DMSO USD 195 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 41 Publications

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzJTWM2OD1yLkCwNFMxOyEQvF2= NILlSWhUSU6JRWK=
IST-MEL1 NEXkW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDVZ40{UUN3ME2wMlAxODRyNzFOwG0> MVTTRW5ITVJ?
NCI-SNU-1 Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTlTGx[UUN3ME2wMlAxOjB5IN88US=> M{fqdnNCVkeHUh?=
FADU MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMECyNFkh|ryP Mk\DV2FPT0WU
C32 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfjTWM2OD1yLkCwN|A1KM7:TR?= MoTKV2FPT0WU
D-566MG MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXpTYpMUUN3ME2wMlAxOzlizszN Mke5V2FPT0WU
LXF-289 NV;FXGpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fubWlEPTB;MD6wNFQyQSEQvF2= MmjKV2FPT0WU
HGC-27 NIXsVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M174VWlEPTB;MD6wNFUyKM7:TR?= Mk\UV2FPT0WU
RPMI-7951 NXfTR49HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMEC3NVch|ryP M2SybXNCVkeHUh?=
HSC-3 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD5TWM2OD1yLkCwPVI6KM7:TR?= MljqV2FPT0WU
MIA-PaCa-2 NEXWXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTyTWM2OD1yLkCxNFA6KM7:TR?= MUjTRW5ITVJ?
KS-1 NVz5WlBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMEGzOVUh|ryP NXXn[3N2W0GQR1XS
CAL-51 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7tTWM2OD1yLkCxOFA2KM7:TR?= NUfKdHhwW0GQR1XS
MDA-MB-361 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnhTZdKSzVyPUCuNFE1QTVizszN NIThcWtUSU6JRWK=
TI-73 NHLCUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnyTWM2OD1yLkCxO|k3KM7:TR?= MmL4V2FPT0WU
AGS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMEG5N|gh|ryP MXnTRW5ITVJ?
NCI-H460 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fN[2lEPTB;MD6wNVk4PCEQvF2= MoKzV2FPT0WU
A204 MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1yzWWlEPTB;MD6wNlI1QSEQvF2= NGL5V3FUSU6JRWK=
CHL-1 NEW1cnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjZToxqUUN3ME2wMlAzOjVzIN88US=> NIfLVo5USU6JRWK=
DU-4475 MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PjbGlEPTB;MD6wNlI3OSEQvF2= NEm0ZYhUSU6JRWK=
CGTH-W-1 M4PleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYOwUGFNUUN3ME2wMlAzOzR7IN88US=> M3zKbnNCVkeHUh?=
HCC2218 M3TzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjpSXltUUN3ME2wMlAzPDl2IN88US=> Mn;WV2FPT0WU
A2780 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfuO20zUUN3ME2wMlAzPTNzIN88US=> NUfyNmc3W0GQR1XS
NCI-H720 MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwMEK1OFYh|ryP NWnZNVg5W0GQR1XS
NCI-N87 NGe3T3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn2VmhKSzVyPUCuNFI2QTNizszN M3HxXXNCVkeHUh?=
CHP-212 M4PqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMEK2Nlgh|ryP MWLTRW5ITVJ?
NCI-H23 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37HTWlEPTB;MD6wNlY3PSEQvF2= NXK0TFFCW0GQR1XS
D-263MG NEW3NlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInESWVKSzVyPUCuNFI4QDZizszN NX;ndG9WW0GQR1XS
ME-180 NGPZ[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK2V5I5UUN3ME2wMlAzQDlzIN88US=> MVnTRW5ITVJ?
SW982 MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMEK5PVkh|ryP NXrWW3ZoW0GQR1XS
OE19 M2XHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEOwO|ch|ryP NYe2VI5bW0GQR1XS
SK-LU-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIryZYJKSzVyPUCuNFMxQDJizszN Mmn0V2FPT0WU
H4 M1;HSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D5c2lEPTB;MD6wN|A6KM7:TR?= MkHUV2FPT0WU
HT-144 NGHVUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMEOwPVMh|ryP NUi5SppGW0GQR1XS
SK-UT-1 NF\2UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEOxO|gh|ryP Mn3UV2FPT0WU
D-336MG MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf1TWM2OD1yLkCzN|A6KM7:TR?= NHXnWHhUSU6JRWK=
MDA-MB-175-VII MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPMTWM2OD1yLkCzN|U1KM7:TR?= NHzwZZVUSU6JRWK=
GAMG Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vlV2lEPTB;MD6wN|Q{PSEQvF2= MWfTRW5ITVJ?
CP50-MEL-B M1\QTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLPcVI4UUN3ME2wMlA{PDVizszN MUjTRW5ITVJ?
OVCAR-5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnQTmxGUUN3ME2wMlA{PDhizszN M1TNVXNCVkeHUh?=
SK-MES-1 NUHSPYp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O5RmlEPTB;MD6wN|YxPiEQvF2= M3TFdXNCVkeHUh?=
VM-CUB-1 NH3PUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXkfGpKSzVyPUCuNFM3PTdizszN MXzTRW5ITVJ?
WM-115 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nKRmlEPTB;MD6wN|c3OiEQvF2= NGPJVmxUSU6JRWK=
DSH1 NE[5WY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMEO4NFch|ryP NGnHfFFUSU6JRWK=
Becker MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;XZWlEPTB;MD6wN|g5PSEQvF2= MUHTRW5ITVJ?
SW962 NYHpNZR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL2emtDUUN3ME2wMlA{QTR3IN88US=> NEm5dFNUSU6JRWK=
TYK-nu M{XYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfiTWM2OD1yLkCzPVg2KM7:TR?= NXrWWnNFW0GQR1XS
HO-1-N-1 Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMESwNlEh|ryP MUHTRW5ITVJ?
T98G M3HDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfvTWM2OD1yLkC0NVA{KM7:TR?= NVPwdllEW0GQR1XS
ACN M4PTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMESxOlIh|ryP MWnTRW5ITVJ?
SW780 NFPHN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M361WWlEPTB;MD6wOFIxOyEQvF2= NW\afVlZW0GQR1XS
Detroit562 MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HvV2lEPTB;MD6wOFI{QSEQvF2= MVzTRW5ITVJ?
BB49-HNC Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMESyOFMh|ryP MnnBV2FPT0WU
HN MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;ST4ZKSzVyPUCuNFQzPzJizszN MWXTRW5ITVJ?
H9 NHjuSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TnOGlEPTB;MD6wOFM4OSEQvF2= NXvsUHUyW0GQR1XS
VA-ES-BJ M1PIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPOTWM2OD1yLkC0OFQ4KM7:TR?= NXTEPHFkW0GQR1XS
MEL-JUSO MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjJ[WdKSzVyPUCuNFQ1PzVizszN M3\PUnNCVkeHUh?=
BT-474 Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XkWWlEPTB;MD6wOFUh|ryP MX7TRW5ITVJ?
CaR-1 MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[yS5R3UUN3ME2wMlA1PTR7IN88US=> NX;rbWtiW0GQR1XS
PSN1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G1eGlEPTB;MD6wOFYxOyEQvF2= M4f6fHNCVkeHUh?=
KYSE-510 NEjDVmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nI[mlEPTB;MD6wOFY1QSEQvF2= NHTMdnZUSU6JRWK=
KP-4 NXjKSYU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\BVGFGUUN3ME2wMlA1PzV|IN88US=> MkjZV2FPT0WU
KYSE-410 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jJW2lEPTB;MD6wOFc4OiEQvF2= MUTTRW5ITVJ?
G-402 NY\tVG44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHKTWM2OD1yLkC0O|g6KM7:TR?= MljWV2FPT0WU
DOK MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMES5NFIh|ryP MlfWV2FPT0WU
COR-L88 M2\Pbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vhVWlEPTB;MD6wOFkyOiEQvF2= NF75NGFUSU6JRWK=
SKG-IIIa MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrzS5VKSzVyPUCuNFQ6QDZizszN MUTTRW5ITVJ?
AN3-CA M4XJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn6OI1KSzVyPUCuNFUh|ryP NXXzXIFxW0GQR1XS
SW48 NXH2eHNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG1TWM2OD1yLkC1NFM6KM7:TR?= MnvHV2FPT0WU
YKG-1 MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlG4TWM2OD1yLkC1NFcyKM7:TR?= NEH4NHZUSU6JRWK=
KYSE-150 MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHsb5NKSzVyPUCuNFUzOzVizszN NYLScpVVW0GQR1XS
HuO-3N1 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMEWyN|ch|ryP MUfTRW5ITVJ?
LB1047-RCC M2iwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMEWyPVYh|ryP MXTTRW5ITVJ?
NCI-H2030 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLyNYpyUUN3ME2wMlA2PDF2IN88US=> M3TqdHNCVkeHUh?=
YH-13 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\DOW1KSzVyPUCuNFU4OjJizszN MorQV2FPT0WU
5637 M1:0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M132OWlEPTB;MD6wOVc1KM7:TR?= MmjZV2FPT0WU
LOXIMVI MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW0TWM2OD1yLkC1PFczKM7:TR?= NHr0fHlUSU6JRWK=
GT3TKB MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\oZodKSzVyPUCuNFU6PDJizszN NELGVJhUSU6JRWK=
TCCSUP NXKzWmN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEW5OlQh|ryP MnvyV2FPT0WU
EPLC-272H NGrXZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TpTGlEPTB;MD6wOlIxPSEQvF2= NYK5eY9rW0GQR1XS
LU-99A M{jS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvtS3doUUN3ME2wMlA3OjN5IN88US=> NHz6TpRUSU6JRWK=
NCI-H1755 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInBOYdKSzVyPUCuNFY{PDFizszN NUG2OoNPW0GQR1XS
KM12 M2S4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwME[zOFgh|ryP NUnzcZVHW0GQR1XS
SF295 M4HDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17SXGlEPTB;MD6wOlQ2OiEQvF2= MXjTRW5ITVJ?
MZ2-MEL MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwME[1OVMh|ryP NVnsTmhvW0GQR1XS
HEC-1 Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT3e5FKSzVyPUCuNFY2QDhizszN NWez[Wd6W0GQR1XS
SW684 NFnaV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLVTWM2OD1yLkC2OVkyKM7:TR?= MknrV2FPT0WU
SF539 NUXYW5NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7jTWM2OD1yLkC2OlgyKM7:TR?= MnnXV2FPT0WU
GMS-10 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTFToRKSzVyPUCuNFY3QTlizszN NX\6bHFqW0GQR1XS
MV-4-11 NV7sOYt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\3TWM2OD1yLkC2PFA{KM7:TR?= MXfTRW5ITVJ?
HT-29 M{\u[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HFU2lEPTB;MD6wOlkyQSEQvF2= MoHrV2FPT0WU
23132-87 NH23XmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofkTWM2OD1yLkC2PVUh|ryP MVfTRW5ITVJ?
SW620 NHrzdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXaXnVWUUN3ME2wMlA4ODJ4IN88US=> NHSxXFlUSU6JRWK=
HCC1806 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMEexN|Eh|ryP MX;TRW5ITVJ?
Hs-578-T NYPybHRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMEeyNFgh|ryP MXfTRW5ITVJ?
A2058 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXGTWM2OD1yLkC3NlI5KM7:TR?= MoTNV2FPT0WU
MEL-HO NW\lS2RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1OzdWlEPTB;MD6wO|I2PSEQvF2= MmrwV2FPT0WU
HCC2998 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq2W|JFUUN3ME2wMlA4OzR5IN88US=> NGHPWlNUSU6JRWK=
HuO9 M3;IRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMEe1PFkh|ryP MV;TRW5ITVJ?
CAL-39 MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f4cmlEPTB;MD6wO|c3PiEQvF2= M1HPSXNCVkeHUh?=
M14 NUDrTlU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rIbGlEPTB;MD6wO|kyOyEQvF2= NXTIbm9PW0GQR1XS
BFTC-909 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;4WGlEPTB;MD6wO|k3QSEQvF2= M1nSPXNCVkeHUh?=
TE-11 NWDqUIhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;RTWM2OD1yLkC3PVk3KM7:TR?= MkXuV2FPT0WU
TGBC1TKB M4TId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHjTWM2OD1yLkC4NFQ{KM7:TR?= MXfTRW5ITVJ?
L-363 M3rYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMEiyNFYh|ryP MVHTRW5ITVJ?
A431 NXLwbGtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHDcnJKSzVyPUCuNFgzOSEQvF2= MVXTRW5ITVJ?
MKN45 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMEiyNVkh|ryP NVSzOXZIW0GQR1XS
HT-1080 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMEi0N|kh|ryP MlLSV2FPT0WU
OVCAR-8 NWLEXoRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPmR5FOUUN3ME2wMlA5PjJ{IN88US=> MoX3V2FPT0WU
LCLC-97TM1 NHjTe5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrveIdEUUN3ME2wMlA5PzJ6IN88US=> NGO3cXVUSU6JRWK=
M059J M1u3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjNXFlKSzVyPUCuNFkxOjdizszN NX\4e|lKW0GQR1XS
SK-MEL-2 MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TkOmlEPTB;MD6wPVA3KM7:TR?= NWXZcYhpW0GQR1XS
TE-1 NWfHdYk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDpXoFWUUN3ME2wMlA6OjB2IN88US=> MXPTRW5ITVJ?
KYSE-180 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwMEmyOlIh|ryP NVKyc49IW0GQR1XS
D-247MG NYDFd2FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\GTWM2OD1yLkC5OFU2KM7:TR?= NIXOcppUSU6JRWK=
8-MG-BA MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMEm0O|Ih|ryP M33jSHNCVkeHUh?=
NCI-H1792 NH7OVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;BTWM2OD1yLkC5OlE5KM7:TR?= MVTTRW5ITVJ?
MCF7 NYfXU5E{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLBTWM2OD1yLkC5Olc4KM7:TR?= NVmwUlZDW0GQR1XS
NCI-H2122 MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMEm3OFUh|ryP MlX1V2FPT0WU
EFO-27 NX3wSGlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXjXVJKSzVyPUCuNFk6QTdizszN Ml\nV2FPT0WU
LB2241-RCC M3za[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHuTWM2OD1yLkGwNFU1KM7:TR?= MXzTRW5ITVJ?
SN12C MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Xi[GlEPTB;MD6xNFExPyEQvF2= NGfaVHZUSU6JRWK=
A498 NHu1NlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnzcZZVUUN3ME2wMlExOThizszN NX7oelNNW0GQR1XS
PANC-03-27 NGPrWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTMTWM2OD1yLkGwNlg3KM7:TR?= MULTRW5ITVJ?
NCI-H1581 NEHMW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMUCyPUDPxE1? M3;3SnNCVkeHUh?=
U-87-MG NFnCOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;xcXpTUUN3ME2wMlExOzB5IN88US=> NYjtO2pDW0GQR1XS
G-401 M4LsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnFOHhMUUN3ME2wMlExOzV|IN88US=> MVTTRW5ITVJ?
SiHa M{jBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMUC0PFYh|ryP NVLOPXV{W0GQR1XS
U251 NFHyeHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\Jb5pXUUN3ME2wMlExPTJ3IN88US=> NH7TbJhUSU6JRWK=
MMAC-SF MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLCTWM2OD1yLkGwOVMyKM7:TR?= MkfqV2FPT0WU
BB65-RCC NETZVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;hcGxZUUN3ME2wMlExPTV2IN88US=> NEixdGpUSU6JRWK=
NKM-1 NIjaNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLxbY1sUUN3ME2wMlExPjZ4IN88US=> M1LPV3NCVkeHUh?=
HD-MY-Z MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDhfYpKSzVyPUCuNVA5PzNizszN NH;5dpdUSU6JRWK=
TGBC11TKB NYD3NGZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n6PWlEPTB;MD6xNFkxOyEQvF2= M4D5[3NCVkeHUh?=
COLO-679 NWe3PVZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rpR2lEPTB;MD6xNVIyOSEQvF2= M1HPOnNCVkeHUh?=
TE-8 NX64T|k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjufmxKSzVyPUCuNVEzPjRizszN NF7zcFlUSU6JRWK=
SK-MEL-28 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nGWmlEPTB;MD6xNVMzOSEQvF2= NUfI[mtyW0GQR1XS
SH-4 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17rd2lEPTB;MD6xNVM2PiEQvF2= MVHTRW5ITVJ?
KALS-1 M3HqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVOyXJE{UUN3ME2wMlEyOzl|IN88US=> NYL0eVdOW0GQR1XS
RKO NYPXWYx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LFeGlEPTB;MD6xNVc3PCEQvF2= M1jqPXNCVkeHUh?=
OMC-1 NITlRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjMWIg{UUN3ME2wMlEyPzl5IN88US=> M17JSnNCVkeHUh?=
BT-549 NVvsUlVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvyV|JKSzVyPUCuNVE4QTlizszN NUDONmFjW0GQR1XS
NCI-H28 MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMUG4NVch|ryP NUHVTmdHW0GQR1XS
RXF393 NF7GeVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHH[4xKSzVyPUCuNVE6QDJizszN Mny2V2FPT0WU
COLO-829 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDpd5hKSzVyPUCuNVIxODVizszN NILxOWFUSU6JRWK=
HMV-II MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XrVmlEPTB;MD6xNlAzKM7:TR?= M4D3cXNCVkeHUh?=
SW1990 NHztfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrNbXFKSzVyPUCuNVIyPTdizszN NX;PemRiW0GQR1XS
NCI-H1437 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrwO3hKSzVyPUCuNVIyPTdizszN MmPpV2FPT0WU
SNB75 NV[4O3JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjGPWRKSzVyPUCuNVIyPjlizszN NETU[oRUSU6JRWK=
EW-3 MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW3TWM2OD1yLkGyOlYyKM7:TR?= MorJV2FPT0WU
SAS MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrYRYRTUUN3ME2wMlEzPjlizszN MX3TRW5ITVJ?
NCI-H1666 NY[zUJdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\FZWhbUUN3ME2wMlEzPzd2IN88US=> M2LGenNCVkeHUh?=
A375 M4nod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuxTWM2OD1yLkGyO|c5KM7:TR?= MoTrV2FPT0WU
CAMA-1 NWKxW4R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP3WWZRUUN3ME2wMlEzQTJ2IN88US=> MmLSV2FPT0WU
HuP-T4 M1T2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMUK5OFMh|ryP NYrDNWJXW0GQR1XS
NCI-H292 NYjEOnprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD0WJFLUUN3ME2wMlE{OTFizszN MkDNV2FPT0WU
PC-14 M13sS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M365WWlEPTB;MD6xN|IyOSEQvF2= NXLSeIxwW0GQR1XS
BPH-1 MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofRTWM2OD1yLkGzOFEh|ryP MkDMV2FPT0WU
GAK MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnB[4ZWUUN3ME2wMlE{PTZ5IN88US=> MkjIV2FPT0WU
VMRC-RCZ MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMUO3OlIh|ryP MVzTRW5ITVJ?
SK-MEL-24 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTHTWM2OD1yLkGzPFch|ryP MVrTRW5ITVJ?
LB831-BLC M4WzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Hl[mlEPTB;MD6xN|g5OyEQvF2= NIPmbVlUSU6JRWK=
NCI-H2452 Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfNTWM2OD1yLkGzPVU3KM7:TR?= M321VHNCVkeHUh?=
RT-112 MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3VWFVtUUN3ME2wMlE1ODN3IN88US=> M1PET3NCVkeHUh?=
GP5d Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjvOppuUUN3ME2wMlE1OTB2IN88US=> M{XxeXNCVkeHUh?=
LC-2-ad NIfNNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOyTWM2OD1yLkG0NVIyKM7:TR?= NWDtOYE1W0GQR1XS
MPP-89 M1fJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMUSxNlUh|ryP MYXTRW5ITVJ?
NUGC-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS3TWM2OD1yLkG0OFc5KM7:TR?= NYDiZ4l3W0GQR1XS
GI-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMUS1OVgh|ryP Ml\CV2FPT0WU
HCC1419 NXzXU4NPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMUS1O|Yh|ryP M4\6VnNCVkeHUh?=
SW1573 M3nXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjkXIJKSzVyPUCuNVQ4PThizszN MV3TRW5ITVJ?
NCI-H2347 Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LLcWlEPTB;MD6xOFg{QSEQvF2= NGjhcoRUSU6JRWK=
Mewo MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnxTWM2OD1yLkG0PFg6KM7:TR?= MWjTRW5ITVJ?
639-V MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPNTWM2OD1yLkG1NFE{KM7:TR?= NELPToxUSU6JRWK=
AsPC-1 NFmzeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;vfINKSzVyPUCuNVUzOjVizszN MnLnV2FPT0WU
NCI-H1648 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT4TWM2OD1yLkG1NlMzKM7:TR?= NGrGendUSU6JRWK=
786-0 NWK0VoZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;5WGlEPTB;MD6xOVM5OSEQvF2= M4D6W3NCVkeHUh?=
ETK-1 MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu1TWM2OD1yLkG1PUDPxE1? MkLXV2FPT0WU
BxPC-3 M4Hrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTTSVVQUUN3ME2wMlE2QTZ4IN88US=> NV;CfJNQW0GQR1XS
CAL-62 NF30fWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMU[xOlkh|ryP M2\5WnNCVkeHUh?=
HCC1937 NVPBOWd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\HTWM2OD1yLkG2Nlc2KM7:TR?= M3i5d3NCVkeHUh?=
NCI-H1299 M1myZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMU[yPFUh|ryP MX7TRW5ITVJ?
SW1088 NIW1d3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMU[0NVMh|ryP NYPjUFd1W0GQR1XS
FTC-133 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PPfWlEPTB;MD6xOlU1KM7:TR?= M{[2OnNCVkeHUh?=
OC-314 NIO5eY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O4WmlEPTB;MD6xOlY6KM7:TR?= MWLTRW5ITVJ?
SCC-9 NVLuephpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XpN2lEPTB;MD6xOlcyPiEQvF2= MUDTRW5ITVJ?
HT-1376 M2[2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqzPWRKSzVyPUCuNVY6OzZizszN NXe5N2tyW0GQR1XS
U-2-OS MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WybmlEPTB;MD6xO|E4OyEQvF2= MX3TRW5ITVJ?
COLO-824 MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;INmlEPTB;MD6xO|I6PCEQvF2= MXjTRW5ITVJ?
BB30-HNC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nHZmlEPTB;MD6xO|M{KM7:TR?= NXvMZVlFW0GQR1XS
NCI-H2087 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnEe2JKSzVyPUCuNVc{PjhizszN NIXyem9USU6JRWK=
NCI-H2170 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHoW3VKSzVyPUCuNVc2OzZizszN NELFWmxUSU6JRWK=
SK-OV-3 NYjHfmI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2raS2lEPTB;MD6xO|U4OSEQvF2= MmnjV2FPT0WU
MZ7-mel NXT1eW8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlftTWM2OD1yLkG3OlQ6KM7:TR?= MW\TRW5ITVJ?
NCI-H650 M4fHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTk[FVKSzVyPUCuNVc3QDJizszN MVHTRW5ITVJ?
KOSC-2 NUHKVYJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMUe3N|Qh|ryP MoLVV2FPT0WU
SCC-4 NUHBZolNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULr[G1TUUN3ME2wMlE4Pzd5IN88US=> NWTjZZlKW0GQR1XS
MDA-MB-157 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnOO5JzUUN3ME2wMlE5ODh{IN88US=> M2H3[nNCVkeHUh?=
KYSE-520 MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjjeIRKSzVyPUCuNVgzKM7:TR?= MXvTRW5ITVJ?
LK-2 MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDDSmNKSzVyPUCuNVg{ODNizszN NIC0PFJUSU6JRWK=
KNS-81-FD MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvwTWM2OD1yLkG4N|k1KM7:TR?= M1PHcXNCVkeHUh?=
IGROV-1 M4\HeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmntTWM2OD1yLkG4OFQ{KM7:TR?= Mki4V2FPT0WU
DEL NVzYfJNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMUi0OUDPxE1? NI\UWYdUSU6JRWK=
NCI-H1395 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DtR2lEPTB;MD6xPFY5OiEQvF2= MkfoV2FPT0WU
JEG-3 NV2w[mpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMUi3NFUh|ryP NXLrU|gzW0GQR1XS
BCPAP M{TLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILFSXBKSzVyPUCuNVg5PzJizszN NELtWZFUSU6JRWK=
CAL-27 NIjkXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XmZWlEPTB;MD6xPVAzOiEQvF2= MkPTV2FPT0WU
RD NHuyPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[zNYpOUUN3ME2wMlE6OTF|IN88US=> Ml7YV2FPT0WU
RVH-421 NWDUPG9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEC0UWlKSzVyPUCuNVkyOTZizszN M4PHd3NCVkeHUh?=
Capan-2 MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPlSXhKSzVyPUCuNVkzPTZizszN NVrHfnZ[W0GQR1XS
COLO-680N NYHoVldjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf3Uo9KSzVyPUCuNVk{PjRizszN MV;TRW5ITVJ?
NCI-H1650 NIjoSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jzbGlEPTB;MD6yNFA2PyEQvF2= MYPTRW5ITVJ?
SBC-5 M{PrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rvfmlEPTB;MD6yNFEyQCEQvF2= M1;vNnNCVkeHUh?=
U031 NF7LRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorJTWM2OD1yLkKwOVQ4KM7:TR?= MXvTRW5ITVJ?
S-117 M4LUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjpUFZuUUN3ME2wMlIxPTZ2IN88US=> NH;TdXRUSU6JRWK=
DoTc2-4510 M4q3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjZT3ZWUUN3ME2wMlIxPzZ7IN88US=> NVeyXlZ2W0GQR1XS
AM-38 NVLCSYhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT4NYNKSzVyPUCuNlA5PDhizszN MVPTRW5ITVJ?
A172 NYHBXWhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rkWGlEPTB;MD6yNVAzOiEQvF2= NFHBcmdUSU6JRWK=
HPAF-II NEfKU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrvWoFKSzVyPUCuNlEzPjRizszN MY\TRW5ITVJ?
769-P NYftR2ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTlTWM2OD1yLkKxNlgh|ryP MYHTRW5ITVJ?
MFE-280 MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:wOmpKSzVyPUCuNlEzQThizszN NED2VJhUSU6JRWK=
TE-9 M3O1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\vTWRKSzVyPUCuNlE4QDZizszN MYTTRW5ITVJ?
C2BBe1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LZUGlEPTB;MD6yNlE6KM7:TR?= MW\TRW5ITVJ?
EoL-1-cell MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMkKyNFMh|ryP M4LPS3NCVkeHUh?=
G-361 NET6SFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nM[2lEPTB;MD6yNlY5OiEQvF2= M2HWZXNCVkeHUh?=
KYSE-270 MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXi[nZEUUN3ME2wMlI{ODh2IN88US=> NIDIO2JUSU6JRWK=
TK10 NITkOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jmWmlEPTB;MD6yN|EyPyEQvF2= NYDZ[2NUW0GQR1XS
ML-2 M4flfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj6TWM2OD1yLkKzNVE6KM7:TR?= NFHPc|dUSU6JRWK=
MHH-ES-1 M{XY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3ETWM2OD1yLkKzOlgyKM7:TR?= NH23ZmJUSU6JRWK=
BHY MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXHN4JKSzVyPUCuNlM3QTFizszN NUDHTY9uW0GQR1XS
LS-513 NXe0[|RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjoTWM2OD1yLkKzPVYyKM7:TR?= NYfZWXk1W0GQR1XS
COLO-678 MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHDTWM2OD1yLkK0NFQ1KM7:TR?= MofyV2FPT0WU
NCI-H747 M336Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVruVIZ1UUN3ME2wMlI1OTZ7IN88US=> MV;TRW5ITVJ?
K5 NICwNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M134Z2lEPTB;MD6yOFM5KM7:TR?= MWDTRW5ITVJ?
OS-RC-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILxWJVKSzVyPUCuNlQ2ODlizszN Mn3sV2FPT0WU
KINGS-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDuTWM2OD1yLkK0OVI6KM7:TR?= NXW2VldRW0GQR1XS
SCC-25 M3\ET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnT6TWM2OD1yLkK0OVY{KM7:TR?= Mmr0V2FPT0WU
CAPAN-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMkS3PFMh|ryP NHHxOYVUSU6JRWK=
ESS-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHQR5BKSzVyPUCuNlQ5ODVizszN MkPWV2FPT0WU
TE-6 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfsRlI1UUN3ME2wMlI2PzVizszN NWrqU2JyW0GQR1XS
LB2518-MEL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXKO4ZKSzVyPUCuNlU4PzdizszN M3jTVXNCVkeHUh?=
COLO-800 NWntWZFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3KdXFKSzVyPUCuNlU5OTJizszN MmDTV2FPT0WU
LU-134-A MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjkb3hKSzVyPUCuNlYyOzZizszN NVO1WGtYW0GQR1XS
NCI-H1155 NXruPGtvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT2O5ROUUN3ME2wMlI3OTZ{IN88US=> M{jEZXNCVkeHUh?=
MFM-223 Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnSTJNKSzVyPUCuNlY{PjNizszN MnLOV2FPT0WU
HTC-C3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm0OG5lUUN3ME2wMlI3PTB4IN88US=> MWnTRW5ITVJ?
HCT-116 MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLvPIFKSzVyPUCuNlY2QTlizszN MkHkV2FPT0WU
Ca-Ski M32zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXETWM2OD1yLkK2Olc5KM7:TR?= NW\YRYRPW0GQR1XS
SBC-1 NWC3SJNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDZV4FPUUN3ME2wMlI3PzR{IN88US=> MWPTRW5ITVJ?
NB69 M3\ifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHzR2RpUUN3ME2wMlI4ODh5IN88US=> Ml22V2FPT0WU
J82 NFvRSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVWzUFZLUUN3ME2wMlI4OjZ3IN88US=> MlrEV2FPT0WU
U-118-MG M{e1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMke1O|kh|ryP NGTPUXdUSU6JRWK=
NCI-H1355 MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFznUVNKSzVyPUCuNlgxPzRizszN MV7TRW5ITVJ?
NCI-H1048 MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rDT2lEPTB;MD6yPFk2PiEQvF2= MXHTRW5ITVJ?
SW954 MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMkmyNlch|ryP NFvPW21USU6JRWK=
NMC-G1 MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17NXWlEPTB;MD6yPVI4PyEQvF2= M{P0fXNCVkeHUh?=
SW1710 M4Dn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXKTWM2OD1yLkK5OFk1KM7:TR?= NFW1d3BUSU6JRWK=
KY821 NGfFWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULzdXlIUUN3ME2wMlI6QDd{IN88US=> NWqwPIhJW0GQR1XS
HCC38 NGPxU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwM{CwO|gh|ryP NUP3fFM2W0GQR1XS
NCI-SNU-5 NFjQUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DTTmlEPTB;MD6zNFU1KM7:TR?= Mon6V2FPT0WU
ES8 NGf1bW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\r[2lEPTB;MD6zNFc5PCEQvF2= NIPTcXZUSU6JRWK=
COLO-792 NYHqRlVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwM{GyOVEh|ryP NFH6ZnhUSU6JRWK=
BFTC-905 M2LVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NICybY5KSzVyPUCuN|E2OjFizszN MknLV2FPT0WU
ChaGo-K-1 NWLMS4J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\Be2lKSzVyPUCuN|E4OTVizszN NYjLR2RSW0GQR1XS
Daoy MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvHNmdPUUN3ME2wMlMyPzJ|IN88US=> MYjTRW5ITVJ?
SJSA-1 NWLNS3E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIGxNotKSzVyPUCuN|E5PDdizszN M2fxdnNCVkeHUh?=
KNS-62 M325W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrGTWM2OD1yLkOyNFg5KM7:TR?= NGTtV3ZUSU6JRWK=
CAKI-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL3TWM2OD1yLkOyNVEyKM7:TR?= MnSzV2FPT0WU
UACC-62 NWfNbmJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwM{KyNlch|ryP NIn3coRUSU6JRWK=
HuCCT1 MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHTVoVKSzVyPUCuN|IzQDNizszN MkXiV2FPT0WU
CTB-1 MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DMWmlEPTB;MD6zNlc2OyEQvF2= MlHCV2FPT0WU
NTERA-S-cl-D1 M2Hme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzqTWM2OD1yLkOyPFM3KM7:TR?= NFHOXY5USU6JRWK=
T-24 NXXvV|JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;DRpN6UUN3ME2wMlM{OTV7IN88US=> MV;TRW5ITVJ?
KYSE-70 NYnNVJRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu0NVNKSzVyPUCuN|MzQDNizszN NGn6Z41USU6JRWK=
SW626 NYLkOZJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwM{O1N|Ih|ryP Mo[3V2FPT0WU
LB996-RCC MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLOTWM2OD1yLkOzOlE6KM7:TR?= NH3X[W5USU6JRWK=
DMS-273 NHnWRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwM{O5NVYh|ryP NVLz[HJLW0GQR1XS
SW1783 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwM{O5PVch|ryP NWfIXXhyW0GQR1XS
KU812 NH3vZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwM{SwN|gh|ryP NWPHSXI1W0GQR1XS
HSC-2 M1fx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnCVnJuUUN3ME2wMlM1ODV|IN88US=> M{jUO3NCVkeHUh?=
A3-KAW NHfwWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwM{SxOlIh|ryP NV7Qc3h7W0GQR1XS
COLO-684 M4\nUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDINWMzUUN3ME2wMlM1PTBzIN88US=> NH3NSJFUSU6JRWK=
NCI-H2405 NV;FdlRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\u[GlEPTB;MD6zOFY{OSEQvF2= MWPTRW5ITVJ?
NCI-H2228 M4LBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXLS2tKSzVyPUCuN|U{PTdizszN MWfTRW5ITVJ?
NB13 NWriV2lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4njRmlEPTB;MD6zOlgzQSEQvF2= NXzYV5VUW0GQR1XS
no-11 M1jDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzV[3lUUUN3ME2wMlM3QTVizszN MXLTRW5ITVJ?
DK-MG MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HvT2lEPTB;MD6zO|E5QCEQvF2= MYHTRW5ITVJ?
NBsusSR NFvwb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwM{eyPFUh|ryP NILTPGxUSU6JRWK=
KP-N-YS NXTFU2k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj2TWM2OD1yLkO3OFY{KM7:TR?= NHHyeI1USU6JRWK=
CFPAC-1 NIrnZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwM{e1NVgh|ryP MUfTRW5ITVJ?
KARPAS-45 M2fqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHKZY1UUUN3ME2wMlM4QDZ{IN88US=> NWnydmN1W0GQR1XS
NCI-H1793 M4W5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\6ZoJCUUN3ME2wMlM5PTFizszN M3q0SnNCVkeHUh?=
HCE-T MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf6XXpKSzVyPUCuN|g3ODNizszN NX\peWFSW0GQR1XS
NCI-H520 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LKcmlEPTB;MD6zPFcxOyEQvF2= MVjTRW5ITVJ?
HCC2157 M2HJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36xdmlEPTB;MD6zPFc5OSEQvF2= NHm3bpRUSU6JRWK=
EW-18 M1O2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\sSWtKSzVyPUCuN|g6PDFizszN NIDUb5dUSU6JRWK=
RO82-W-1 NYKwblFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXKSXE3UUN3ME2wMlM6Pjl7IN88US=> NWnuR4NGW0GQR1XS
HuP-T3 NHPsTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPIUIlMUUN3ME2wMlQxOTR|IN88US=> MonFV2FPT0WU
PANC-10-05 M1S5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XGNWlEPTB;MD60NVE4KM7:TR?= NEfuZXhUSU6JRWK=
NCI-H1703 M4HvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jDVmlEPTB;MD60NVQ1PiEQvF2= NIC4W49USU6JRWK=
TE-10 NUnlV4dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Oy[mlEPTB;MD60NVQ1PyEQvF2= M4LmPHNCVkeHUh?=
HOS M3PoNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn0ZWtnUUN3ME2wMlQyPjh{IN88US=> NIC1RpRUSU6JRWK=
LN-405 Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jHZmlEPTB;MD60NVY5PyEQvF2= NVLwV4pCW0GQR1XS
A427 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXmS5BKSzVyPUCuOFE6QDFizszN NVjXXWJVW0GQR1XS
CAL-12T Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwNEK3PEDPxE1? NFjwfm9USU6JRWK=
SW756 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLXTWM2OD1yLkS0NVg{KM7:TR?= NYLsVoZ1W0GQR1XS
YAPC MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe4[2ZKSzVyPUCuOFUxQCEQvF2= NVL5bZlwW0GQR1XS
GOTO Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnSwTWM2OD1yLkS1NVYh|ryP MlTzV2FPT0WU
C3A MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETYPJRKSzVyPUCuOFU1OzdizszN MoPYV2FPT0WU
UM-UC-3 NFu5XZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f4VmlEPTB;MD60OVQ4KM7:TR?= NUfobVJkW0GQR1XS
NCI-H1573 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr3SYxKSzVyPUCuOFU2PjlizszN MnqzV2FPT0WU
LS-411N M2XkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PKXmlEPTB;MD60OlUzPyEQvF2= NFjMVldUSU6JRWK=
COR-L23 NHe0dZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHFWWtKSzVyPUCuOFY4PjRizszN NIrjOpZUSU6JRWK=
HCE-4 MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwNEe0OFYh|ryP NIDySpZUSU6JRWK=
NCI-H2291 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwNEe4PVYh|ryP NGe1cFBUSU6JRWK=
A101D NUfudJYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f2cWlEPTB;MD60PFA2OyEQvF2= M2C2WHNCVkeHUh?=
HT-3 M4jqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTmTWM2OD1yLkS4NlE4KM7:TR?= MVnTRW5ITVJ?
HOP-62 NXP3T|B5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTuTWM2OD1yLkS5PFY2KM7:TR?= NFTL[YxUSU6JRWK=
PC-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwNUG1NFch|ryP MUfTRW5ITVJ?
CTV-1 NWjWWHBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfPTWM2OD1yLkWyOlY6KM7:TR?= NInHW3dUSU6JRWK=
PANC-08-13 NVXsOlhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwNUOxO|ch|ryP NYOyclU3W0GQR1XS
CAL-120 NGX0bnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7CTWM2OD1yLkWzN|k6KM7:TR?= MVXTRW5ITVJ?
UMC-11 NFy1R5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\2cWlEPTB;MD61OVI{PCEQvF2= NIn5ZmJUSU6JRWK=
MSTO-211H M4HhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnES|ZLUUN3ME2wMlU2PzZ{IN88US=> MoX6V2FPT0WU
NCI-H2126 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwNU[4NVUh|ryP MWrTRW5ITVJ?
SNU-C2B MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwNUe5O|ch|ryP MUXTRW5ITVJ?
DBTRG-05MG M4O4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3MfplKSzVyPUCuOVgxPTNizszN NH;ubppUSU6JRWK=
MKN1 MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwNUi3PFMh|ryP NVzINFRuW0GQR1XS
ES3 M4XLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwNUmxNlQh|ryP NW\PZW9TW0GQR1XS
OVCAR-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT0OlVKSzVyPUCuOVk{PDFizszN MXrTRW5ITVJ?
ACHN MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7M[lRKSzVyPUCuOlA2PjlizszN NETsVnFUSU6JRWK=
SW872 NEC2WVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwNkC3OlMh|ryP MYfTRW5ITVJ?
CP66-MEL M{TRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwNkC5Olkh|ryP NXzkdpUxW0GQR1XS
NCI-H661 M1ThOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULsVnQ1UUN3ME2wMlYyOTB2IN88US=> Mn24V2FPT0WU
UACC-893 M4S3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXCRVhKSzVyPUCuOlM3QDFizszN MV3TRW5ITVJ?
JVM-3 NGPYS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzIdJlKSzVyPUCuOlM5ODRizszN NEPlTXNUSU6JRWK=
SF268 NGDoZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T4emlEPTB;MD62OFM1QSEQvF2= M2\uOXNCVkeHUh?=
OCI-AML2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG4R5EzUUN3ME2wMlY2Ozl5IN88US=> NIjIe2FUSU6JRWK=
RPMI-8226 NEOyUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnucm9UUUN3ME2wMlY3OzJ|IN88US=> MlL6V2FPT0WU
MKN28 M3zycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke3TWM2OD1yLk[2OlI1KM7:TR?= NIjF[JVUSU6JRWK=
MDA-MB-453 NGnpV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwNkexPEDPxE1? NFW1XWFUSU6JRWK=
BV-173 NGnWT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwNki2O|kh|ryP NY\qVGg4W0GQR1XS
NCI-H358 NF;RTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TJcGlEPTB;MD62PFczPiEQvF2= MWPTRW5ITVJ?
NCI-H1651 NIX1Z|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33xZWlEPTB;MD63JO69VQ>? NIPCUGdUSU6JRWK=
MDA-MB-415 M4rHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDpVWNTUUN3ME2wMlcxQDJ7IN88US=> NY\GW4MxW0GQR1XS
8305C MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwN{K0PVgh|ryP MoLPV2FPT0WU
EFM-19 NGPxN|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX2TWM2OD1yLkezOlcyKM7:TR?= M{izenNCVkeHUh?=
RERF-LC-MS M2HDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\Zb2lEPTB;MD63OFYyOyEQvF2= MV;TRW5ITVJ?
A388 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHteJROUUN3ME2wMlc3PDZ5IN88US=> NHTJOW1USU6JRWK=
GI-ME-N MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwN{eyN|Uh|ryP NV7QNYpRW0GQR1XS
IGR-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzwOlVXUUN3ME2wMlc6ODR|IN88US=> M335UnNCVkeHUh?=
LNCaP-Clone-FGC M{XteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD2TWM2OD1yLkiwNFA1KM7:TR?= MWLTRW5ITVJ?
SK-MEL-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFThSohKSzVyPUCuPFE2ODhizszN M{jGTHNCVkeHUh?=
UACC-257 Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DkOGlEPTB;MD64NlI{OSEQvF2= NWC2V5RWW0GQR1XS
OE33 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwOEWxNFEh|ryP MWjTRW5ITVJ?
QIMR-WIL MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjLeHZKSzVyPUCuPFUyPDFizszN NIfnWZNUSU6JRWK=
NCI-H2009 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwOEWzNVEh|ryP NV;ZeZlOW0GQR1XS
NCI-H522 NITnPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33N[mlEPTB;MD64O|c5OyEQvF2= MWTTRW5ITVJ?
Saos-2 MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrIO49KSzVyPUCuPFc5PzFizszN MWrTRW5ITVJ?
NB17 NH7hXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwOEiwNlUh|ryP MkHaV2FPT0WU
D-392MG NIHqc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHMTWM2OD1yLki5N|U3KM7:TR?= NHfscpRUSU6JRWK=
SHP-77 NXHKXpkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\0Smp3UUN3ME2wMlkxPDh3IN88US=> NXW1WGxOW0GQR1XS
SK-MEL-30 MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzlbGRKSzVyPUCuPVEyQDVizszN M{f4bnNCVkeHUh?=
GCIY MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XhVmlEPTB;MD65NVg1OyEQvF2= NHm2fnVUSU6JRWK=
HCC70 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorkTWM2OD1yLkmyNFU6KM7:TR?= MYrTRW5ITVJ?
LU-65 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3Yd4tbUUN3ME2wMlkzPTlzIN88US=> NX\ZWXRRW0GQR1XS
NCI-H1563 NWjtb3JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrTV4VKSzVyPUCuPVQ5PjVizszN MofQV2FPT0WU
KURAMOCHI MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XsbmlEPTB;MD65OVE6OiEQvF2= NUT5[W1oW0GQR1XS
PA-1 NV7ifoppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwOUW0NlQh|ryP Ml;mV2FPT0WU
NOS-1 NGCxVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PB[2lEPTB;MD65O|Q5QSEQvF2= NF7hdGhUSU6JRWK=
NCI-H69 NIXhPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnGbJRLUUN3ME2wMlk4PjN2IN88US=> MV;TRW5ITVJ?
KYSE-450 M2r5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfEXXZKSzVyPUCuPVg3OjZizszN MofuV2FPT0WU
8505C M{jpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C0U2lEPTB;MD65PVk5OiEQvF2= M3HocnNCVkeHUh?=
TGBC24TKB NUDYWHJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj3W|hKSzVyPUGuNFAxQDRizszN MVfTRW5ITVJ?
PFSK-1 MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HsRmlEPTB;MT6wNVQzQCEQvF2= NXiwTnU4W0GQR1XS
EKVX NVrUXXJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwMEOxNlEh|ryP MV;TRW5ITVJ?
RCM-1 M1rwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDoVFlnUUN3ME2xMlA2PTB5IN88US=> NHOyO|BUSU6JRWK=
SW900 NGXSN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG1WJdKSzVyPUGuNFc5OyEQvF2= M3;RVnNCVkeHUh?=
D-542MG M{LsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwMEe4OVUh|ryP MVrTRW5ITVJ?
SK-PN-DW M3:zPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzJV2dSUUN3ME2xMlExODV4IN88US=> Mke2V2FPT0WU
NCI-H727 NI[xVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwMUCxOVQh|ryP M2C5cHNCVkeHUh?=
SW837 M{HjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nhOGlEPTB;MT6xNFk2PCEQvF2= M{LmRnNCVkeHUh?=
BT-20 NIK3eFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTqWY9KSzVyPUGuNVEzODRizszN NITJZpZUSU6JRWK=
RH-18 NX;6UVFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PQOWlEPTB;MT6xN|ExOyEQvF2= M1;3WXNCVkeHUh?=
TE-12 MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zqZmlEPTB;MT6xN|M{OyEQvF2= NIPuR3ZUSU6JRWK=
NB10 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFwMUOzOFQh|ryP NWfMSWNWW0GQR1XS
AU565 M3\PWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTCTWM2OD1zLkG1PVc{KM7:TR?= NUXCTIF5W0GQR1XS
OAW-42 NU\XTYFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWmzfnR7UUN3ME2xMlE5OzB4IN88US=> MWPTRW5ITVJ?
DJM-1 M2rUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{WyS2lEPTB;MT6xPVg5OSEQvF2= M3\ZXXNCVkeHUh?=
HH NHzGSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETPcJZKSzVyPUGuNlM5OzFizszN NW\TZVdOW0GQR1XS
LAMA-84 NUjoU5BiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7KXmFKSzVyPUGuNlc{QTRizszN M{ezZXNCVkeHUh?=
KNS-42 MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DoXmlEPTB;MT6zNFI6PiEQvF2= MkG5V2FPT0WU
NCI-H2052 M4LERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzGTWM2OD1zLkOwOVA4KM7:TR?= MoLXV2FPT0WU
MLMA NET5fIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTjb2hZUUN3ME2xMlMzPDB5IN88US=> MYHTRW5ITVJ?
NB12 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFwM{W2N|Yh|ryP NYnaXlBzW0GQR1XS
NCI-H1838 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPJUFBQUUN3ME2xMlM3OzB4IN88US=> MlzUV2FPT0WU
NCI-H526 MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTETWM2OD1zLkO3PFU{KM7:TR?= NYe0doM4W0GQR1XS
LS-123 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjaTWM2OD1zLkO5NFk1KM7:TR?= MYHTRW5ITVJ?
HDLM-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnaS5dKSzVyPUGuN|kzPzFizszN MWrTRW5ITVJ?
MC-IXC Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwNEKzO|Eh|ryP NGfsXm5USU6JRWK=
HCT-15 Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{frWGlEPTB;MT60N|A3QCEQvF2= NFXwd4JUSU6JRWK=
NCI-H596 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP5ZldKSzVyPUGuOFUxPjFizszN NEG3U41USU6JRWK=
ZR-75-30 M2XsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPiXItQUUN3ME2xMlQ4ODh{IN88US=> NX;neFR{W0GQR1XS
A704 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojCTWM2OD1zLk[2OVY{KM7:TR?= M1:0cXNCVkeHUh?=
OVCAR-4 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX3TWM2OD1zLk[5OlA4KM7:TR?= M4PX[HNCVkeHUh?=
SW1417 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TVWGlEPTB;MT63Nlg1QSEQvF2= MoLYV2FPT0WU
CAS-1 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvGTIxKSzVyPUGuO|M6OzZizszN NXS0Z4l4W0GQR1XS
IST-SL1 M3jyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfKTWM2OD1zLke5O|U6KM7:TR?= MnjqV2FPT0WU
A253 NHXsZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PVVWlEPTB;MT64NlI{QSEQvF2= NF;TNnNUSU6JRWK=
EW-16 NV\GS3o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfzbmZKSzVyPUGuPFI5PzVizszN MWHTRW5ITVJ?
SK-NEP-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljlTWM2OD1zLki2PVg5KM7:TR?= M4LPRXNCVkeHUh?=
NCI-H226 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFwOEmzOVkh|ryP NWr6WIdQW0GQR1XS
HOP-92 NHvSNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7ISFJKSzVyPUGuPVYxQTlizszN NVHN[YNVW0GQR1XS
NCI-H441 NEPQWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXPV5FUUUN3ME2yMlAzOzN5IN88US=> NHrqcoNUSU6JRWK=
LU-139 NVvjZXdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfXW|N2UUN3ME2yMlA{OTF2IN88US=> NEfsTHBUSU6JRWK=
SJRH30 MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJwMESyOVMh|ryP MlTMV2FPT0WU
MG-63 M{\GVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPzNnVXUUN3ME2yMlE1OTFzIN88US=> NEDTbGVUSU6JRWK=
NH-12 NHv3N5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TnTGlEPTB;Mj6xOVAxPiEQvF2= MkH6V2FPT0WU
NB7 Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnOxTWM2OD1{LkG5Olc{KM7:TR?= NX;tS5V5W0GQR1XS
LB771-HNC M{[4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnPNmxrUUN3ME2yMlIxPTl3IN88US=> NGjYepdUSU6JRWK=
HCC1569 MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr2TWM2OD1{LkK0OVg{KM7:TR?= NEnqeJJUSU6JRWK=
D-283MED NFWxV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HRNmlEPTB;Mj6yOFc5OiEQvF2= MULTRW5ITVJ?
J-RT3-T3-5 NITrfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX0bYVKSzVyPUKuNlU{PTFizszN MnPNV2FPT0WU
ATN-1 MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnywTWM2OD1{LkOzNFgzKM7:TR?= M176ZnNCVkeHUh?=
HCC1954 NF\ySGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJwM{S0NFgh|ryP MXvTRW5ITVJ?
SCC-15 NV3pW45qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XmPGlEPTB;Mj6zPVMyOiEQvF2= MmPOV2FPT0WU
COLO-668 MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K4W2lEPTB;Mj60N|Ih|ryP NWX3TWwyW0GQR1XS
LB373-MEL-D MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJwNUS2O|ch|ryP Mn3pV2FPT0WU
no-10 M2ezNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDBTWM2OD1{LkW0PVQ4KM7:TR?= MnSzV2FPT0WU
HT-1197 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnQVJVKSzVyPUKuOlMyQDhizszN NHHCZXJUSU6JRWK=
DU-145 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJwN{mxOlIh|ryP MXPTRW5ITVJ?
SK-N-AS M1[wemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj1XYhvUUN3ME2yMlg1Pjl{IN88US=> M3HTOnNCVkeHUh?=
MOLT-4 Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[3bmJKSzVyPUKuPFU{OjJizszN M3rzdnNCVkeHUh?=
EW-22 M4\1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi2TWM2OD1{LkmyPFQyKM7:TR?= M3\KZXNCVkeHUh?=
DB MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\vb2lKSzVyPUKuPVc4PTlizszN MXzTRW5ITVJ?
HL-60 M1;iS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTNwMESzO|Yh|ryP NYLGWm4xW0GQR1XS
SK-N-DZ M{HiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy1OotvUUN3ME2zMlA2ODd3IN88US=> NESyVYtUSU6JRWK=
NY NYO0dVZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmThTWM2OD1|LkC4OVQzKM7:TR?= MVjTRW5ITVJ?
T47D NGDocYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXINZg{UUN3ME2zMlExPTV6IN88US=> NGXEc2ZUSU6JRWK=
NCI-H2029 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzCWIN3UUN3ME2zMlIzPDd5IN88US=> NWPES4xjW0GQR1XS
KARPAS-299 MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\3bVdTUUN3ME2zMlI3ODJ5IN88US=> NHnXOXdUSU6JRWK=
KM-H2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrrOmdIUUN3ME2zMlMxPjhizszN M1XOOXNCVkeHUh?=
CHP-134 NWTSZVJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHuTGd5UUN3ME2zMlQ4OzlizszN M2TNb3NCVkeHUh?=
22RV1 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi2[VRKSzVyPUOuOFkyPjhizszN MoK3V2FPT0WU
NB5 MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrlTWM2OD1|LkWwOlg6KM7:TR?= NXvWUZBFW0GQR1XS
CW-2 MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjZTIdNUUN3ME2zMlU2OzF2IN88US=> NXLYV5ltW0GQR1XS
EFO-21 MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf5bYJ4UUN3ME2zMlU3QTRizszN NGf2em5USU6JRWK=
HuH-7 NYfG[|RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfnWolKSzVyPUOuOVg1OTRizszN NUDJRZFGW0GQR1XS
ALL-PO MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNwNkKzN|Uh|ryP NVeyPJVtW0GQR1XS
EM-2 M1:zZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjzTWM2OD1|Lk[5NFEyKM7:TR?= NXTFWmx[W0GQR1XS
KLE Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nvUmlEPTB;Mz63N|AzQSEQvF2= M4HU[HNCVkeHUh?=
NEC8 NFnNUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTMXlY{UUN3ME2zMlkyQDB6IN88US=> NVH5OlVNW0GQR1XS
KP-N-YN M{PpcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknkTWM2OD1|LkmzOFc3KM7:TR?= NFn2bWNUSU6JRWK=
SK-MEL-1 M3vtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYriVVhxUUN3ME20MlA{PTF6IN88US=> M2DkPXNCVkeHUh?=
CAL-54 NXK4SYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHpXXprUUN3ME20MlA2QTFizszN NVX4O5RyW0GQR1XS
MS-1 NILrfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTRwMU[xOVUh|ryP MXvTRW5ITVJ?
NCI-H209 NWfqb4I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;mVlR2UUN3ME20MlI6QTl7IN88US=> MnPGV2FPT0WU
NOMO-1 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL3ZXhSUUN3ME20MlMzOTNzIN88US=> NWrOdZR1W0GQR1XS
RPMI-2650 NFLiPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILP[WZKSzVyPUSuN|Y{OjdizszN M2jCUXNCVkeHUh?=
NCI-H810 NGDIfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTRwM{m3N|Yh|ryP MmrBV2FPT0WU
Ca9-22 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLYeZlKSzVyPUSuOFU3QTFizszN NI\RbnJUSU6JRWK=
ES4 NFS1[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTRwNEewPVUh|ryP NESxNIxUSU6JRWK=
ES6 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\tTWM2OD12LkS5OlU4KM7:TR?= MWPTRW5ITVJ?
DMS-114 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTRwNUS2PVEh|ryP M13iSXNCVkeHUh?=
ONS-76 Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGm3dVRKSzVyPUSuOVc6PSEQvF2= MnvqV2FPT0WU
K-562 NHfl[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGflSFBKSzVyPUSuO|M5OTRizszN M3jUZnNCVkeHUh?=
MHH-NB-11 NUf2PYVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rucGlEPTB;ND63OVQ3OSEQvF2= Ml\DV2FPT0WU
Calu-3 NIf1dpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHIOpFKSzVyPUSuO|g2PDhizszN MXHTRW5ITVJ?
HT55 NV3PcYJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLkVY9IUUN3ME20Mlg1PTR3IN88US=> NELEPXhUSU6JRWK=
SK-N-FI MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzKelhiUUN3ME20Mlg2ODB7IN88US=> NX24bIdIW0GQR1XS
ES1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrkOmZKSzVyPUSuPFYxPTdizszN MUPTRW5ITVJ?
SF126 Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rmTGlEPTB;ND65N|E5PCEQvF2= MXnTRW5ITVJ?
ES5 Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLBWYNGUUN3ME21MlEzPDJ5IN88US=> M2jrXHNCVkeHUh?=
LoVo NV;ST2ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTVwMUW4O|Eh|ryP M4W4T3NCVkeHUh?=
SNU-387 NWPON2Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX71bnZoUUN3ME21MlMzOzN7IN88US=> MXjTRW5ITVJ?
C8166 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTVwM{[zN|kh|ryP NF[5O2VUSU6JRWK=
LS-1034 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL2TWM2OD13LkSyN|A4KM7:TR?= NYfFVlExW0GQR1XS
GR-ST M{H1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTVwNUKyNFEh|ryP MnTBV2FPT0WU
NCI-H1092 MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrETWM2OD13LkeyPFQ{KM7:TR?= NILkWpdUSU6JRWK=
647-V MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf3THhKSzVyPUWuO|Q4ODZizszN NIXv[5dUSU6JRWK=
EW-13 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTVwN{[2Nlch|ryP MU\TRW5ITVJ?
KGN NHLWPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjFUHFKSzVyPU[uNFk6OjFizszN NYXxeIZEW0GQR1XS
D-423MG NF;jfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\yVFRpUUN3ME22MlQxOjh2IN88US=> NH64TmxUSU6JRWK=
ECC10 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[4cVlKSzVyPUeuNVAyODFizszN NInS[mhUSU6JRWK=
TE-5 NYLvVFlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;3VpI1UUN3ME23MlQyOjl6IN88US=> Mlm0V2FPT0WU
P12-ICHIKAWA NEXJfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCzOItlUUN3ME23MlQ2PTJ|IN88US=> M3\icnNCVkeHUh?=
NCI-H82 M3yze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;G[2lEPTB;Nz60OVcxOSEQvF2= NV[1WZZFW0GQR1XS
NCI-H1993 M3TjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTrTWM2OD15LkizNFY{KM7:TR?= NILZXmNUSU6JRWK=
RH-1 M{WxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDQTWM2OD15Lki1NlQ1KM7:TR?= NFrVeJdUSU6JRWK=
SW948 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vzdWlEPTB;Nz65OlA1QSEQvF2= NYLZdm93W0GQR1XS
CAL-33 NHvKWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLmb2hKSzVyPUeuPVk6OzhizszN M2jwcHNCVkeHUh?=
U-266 M2e1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XtZWlEPTB;OD6xOVc4PyEQvF2= NHjVNmFUSU6JRWK=
CAL-72 NVXhV3FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3VPHY1UUN3ME24MlIxOzJizszN MoHPV2FPT0WU
SNU-423 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO3[4dtUUN3ME25MlM3PjZ4IN88US=> NV\xZohDW0GQR1XS
KG-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rxVWlEPTB;OT61PFQ2PiEQvF2= M1LzTHNCVkeHUh?=
HCC1395 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLoTWM2OD17LkmyN|UzKM7:TR?= NXS2OW5JW0GQR1XS
BE-13 NVntNYdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rRWGlEPTB;MUCuPFg6OiEQvF2= NYLUfGQ5W0GQR1XS
MKN7 NUDLe5ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\0cGlEPTB;MUCuPVc3PSEQvF2= NWP6fW1JW0GQR1XS
697 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTFzLkG0O|Ih|ryP MmPuV2FPT0WU
LU-135 NWnWfYVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrVc2k2UUN3ME2xNU4zOzB5IN88US=> NGDo[lNUSU6JRWK=
ES7 NVrncVJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVftOYo1UUN3ME2xNU4{OzF|IN88US=> M4LiRnNCVkeHUh?=
SK-HEP-1 NViwcpVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7ITWM2OD1zMT63OlQ3KM7:TR?= MWHTRW5ITVJ?
BEN NUDuXXdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXp[YpKSzVyPUGxMlg2OSEQvF2= NW\vU4xRW0GQR1XS
NCI-H1770 MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrzXJdKSzVyPUGyMlEzPiEQvF2= NVXm[lg3W0GQR1XS
SW13 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF{LkG1OFEh|ryP MmfoV2FPT0WU
MZ1-PC NVTpc4ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjxTHY1UUN3ME2xNk42PDV{IN88US=> NW[5ZZlsW0GQR1XS
Mo-T Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP5SGFKSzVyPUGyMlc1OjFizszN NWn0V|Q1W0GQR1XS
HLE MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nFUGlEPTB;MUKuPFIyPSEQvF2= M2jsO3NCVkeHUh?=
RCC10RGB NF[4ZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm1TWM2OD1zMz62O|Eh|ryP Mn;zV2FPT0WU
COLO-320-HSR NHS1RmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPCbXJtUUN3ME2xN{44OzhzIN88US=> M1vTZXNCVkeHUh?=
BHT-101 M332TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjYS5NKSzVyPUGzMlg{PDVizszN NInoZXlUSU6JRWK=
OCUB-M MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTrOplKSzVyPUG0MlE3ODJizszN MkX3V2FPT0WU
MEG-01 NIrIXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHKbFYxUUN3ME2xOE4{PzB6IN88US=> NUjHNYN5W0GQR1XS
RS4-11 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF2Lke0NkDPxE1? NG\EemFUSU6JRWK=
MN-60 M1y5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW2VGRKSzVyPUG0Mlc5QTRizszN NILwTYtUSU6JRWK=
NCI-H1304 NWf6XmYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnCZ2RKSzVyPUG1MlA1OjVizszN NUnheG5uW0GQR1XS
Ramos-2G6-4C10 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF3LkC1PFEh|ryP NGfSUVdUSU6JRWK=
NCI-H2342 M2SzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHUTWM2OD1zNT6yNFQ1KM7:TR?= NGfPbFJUSU6JRWK=
LAN-6 NHjFOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrib3ZKSzVyPUG1MlQ1OTRizszN NVTVVopJW0GQR1XS
JVM-2 M3Htdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme2TWM2OD1zNT61O|Q5KM7:TR?= NXjBZZpiW0GQR1XS
P30-OHK NEW2e2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPwTWM2OD1zNj6wOlE1KM7:TR?= MXrTRW5ITVJ?
C-33-A NEGzeIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XodGlEPTB;MU[uOlIyPCEQvF2= M2fSUHNCVkeHUh?=
RPMI-8866 M{jvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33UPGlEPTB;MU[uPFQ6PiEQvF2= NUjGXHRqW0GQR1XS
NCI-H630 NFjreXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TEOWlEPTB;MU[uPFU{PyEQvF2= NFj1SZNUSU6JRWK=
KYSE-140 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrFPZpzUUN3ME2xO{4zODJ6IN88US=> MlP2V2FPT0WU
T84 NIXnZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K1TWlEPTB;MUiuPFY6PSEQvF2= NXnKPXdIW0GQR1XS
KU-19-19 NGLKdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF6Lkm2NFgh|ryP M2fvPXNCVkeHUh?=
BALL-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HucWlEPTB;MUmuN|M6QSEQvF2= M{XpOHNCVkeHUh?=
Calu-6 Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\KcXB1UUN3ME2xPU41QTJizszN MYXTRW5ITVJ?
EGI-1 NV;z[pBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvRe|ZKSzVyPUG5MlU6QCEQvF2= MX;TRW5ITVJ?
MFH-ino M4jIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\WVWlEPTB;MUmuO|Q2PCEQvF2= MkHsV2FPT0WU
GB-1 NYfBeoVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjHdpBFUUN3ME2yNE4{PTN3IN88US=> MnXVV2FPT0WU
NCI-H1693 M1u3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofTTWM2OD1{MD62OVA2KM7:TR?= NWDUUnNSW0GQR1XS
SW1116 MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWriUmtLUUN3ME2yNE46OzZ{IN88US=> M13QZXNCVkeHUh?=
H-EMC-SS M2XqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXKTWM2OD1{Mj6wOFUh|ryP NYS3cpNzW0GQR1XS
D-502MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfkOoNKSzVyPUKyMlgzPjFizszN NWLFRVhQW0GQR1XS
IA-LM MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDQTWM2OD1{Mz6yOFk{KM7:TR?= NVP6PZVDW0GQR1XS
SW1463 NWHaWndjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTaZ2ZZUUN3ME2yN{44QSEQvF2= NGnYS2FUSU6JRWK=
JAR M3i2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ2LkOyPVMh|ryP NHXifFhUSU6JRWK=
HT NInFfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\BV2lEPTB;MkSuOFc2OyEQvF2= M1vacXNCVkeHUh?=
LCLC-103H M4PpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ2Lki0OFkh|ryP NV2zelFLW0GQR1XS
SNU-449 NFH1d3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rnbmlEPTB;MkSuPFc1OSEQvF2= Mon4V2FPT0WU
KE-37 MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzsZpg3UUN3ME2yOU4xQTJ6IN88US=> NW\Kcm5{W0GQR1XS
NCI-H1623 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDtTWM2OD1{Nz6xN|A{KM7:TR?= M1vFcHNCVkeHUh?=
MOLT-13 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXyTWM2OD1{Nz6zOVE3KM7:TR?= NEe2[mpUSU6JRWK=
COLO-741 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTNzLkOzN|Mh|ryP MV;TRW5ITVJ?
NB6 M{nuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy1U3ZpUUN3ME2zNk4zQDd4IN88US=> NWPncoxrW0GQR1XS
MOLT-16 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS1XmtuUUN3ME2zN{4xODV3IN88US=> NYOyWXB3W0GQR1XS
IST-MES1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn2xTWM2OD1|ND6wOVQyKM7:TR?= NHnZNHhUSU6JRWK=
A4-Fuk M3;vT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLLTWM2OD1|NT6wOlYh|ryP Mk\IV2FPT0WU
CAL-85-1 NHjzdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P2RmlEPTB;M{WuNlgyPyEQvF2= M2TXeXNCVkeHUh?=
CCRF-CEM M4HQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\2TnNKSzVyPUO3MlE2OzZizszN MV\TRW5ITVJ?
HAL-01 M3jGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDQNHZKSzVyPUO4MlQ5QDlizszN NFyzSnFUSU6JRWK=
HEL NFqyWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnmO2pkUUN3ME20N{4{PDB7IN88US=> M{DRcnNCVkeHUh?=
EW-1 NFfPbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXQN4s5UUN3ME20N{41PzZ6IN88US=> MmnGV2FPT0WU
MDA-MB-231 MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi4U5VKSzVyPUS1MlEyQTlizszN MYfTRW5ITVJ?
ABC-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzle2NKSzVyPUS2Mlg2OzhizszN NHr0b5JUSU6JRWK=
NCI-H446 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j6bGlEPTB;NEiuOVA2QCEQvF2= NIL3ZnJUSU6JRWK=
MHH-PREB-1 MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjGTWM2OD12OT62NFA4KM7:TR?= MXHTRW5ITVJ?
DOHH-2 NXPHeI5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTPTWM2OD12OT62OlU3KM7:TR?= M{DJRnNCVkeHUh?=
GCT NVvRb3JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL4TWM2OD12OT62PVc3KM7:TR?= MVTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; 

PubMed: 20090920     


Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control.

EGFR / PDGFR / AKT / MAPK / c-RAS; 

PubMed: 18682579     


17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment.

pAKT / pMAPK / pRb; 

PubMed: 18682579     


The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment.

Cleaved PARP / Survivin; 

PubMed: 18827603     


Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control.

LATS1 / p-LATS1 / YAP / CTGF; 

PubMed: 25712415     


Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF.  The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.

20090920 18682579 18827603 25712415
Immunofluorescence
STAT3; 

PubMed: 27279418     


Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole.

YAP / TAZ; 

PubMed: 25290150     


Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM).

β-catenin / E-cadherin; 

PubMed: 25290150     


Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.

27279418 25290150
Growth inhibition assay
Cell viability; 

PubMed: 18682579     


17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.

18682579
In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
- Collapse

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
- Collapse
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Ethanol 5 mg/mL (8.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+corn oil
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
in solvent
Synonyms CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00103272 Terminated Drug: tanespimycin|Drug: bortezomib Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia National Cancer Institute (NCI) April 2005 Phase 1
NCT00098488 Terminated Drug: tanespimycin|Biological: rituximab B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia National Cancer Institute (NCI) April 2005 Phase 1
NCT00118248 Completed Drug: tanespimycin Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma National Cancer Institute (NCI) December 2004 Phase 2
NCT00098423 Completed Drug: tanespimycin|Drug: cytarabine Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes National Cancer Institute (NCI) November 2004 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Tags: buy Tanespimycin (17-AAG) | Tanespimycin (17-AAG) supplier | purchase Tanespimycin (17-AAG) | Tanespimycin (17-AAG) cost | Tanespimycin (17-AAG) manufacturer | order Tanespimycin (17-AAG) | Tanespimycin (17-AAG) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID